The complement system in schizophrenia.
Several lines of evidence suggest that immunological factors contribute to schizophrenia. Since 1989, the role of complement, a major effector of innate immunity and an adjuvant of adaptive immunity, has been explored in schizophrenia. Increased activity of C1, C3, C4 complement components in schizophrenia has been reported by two or more groups. Two studies on different subject cohorts showed increased MBL-MASP-2 activity in patients versus controls. More then one report indicated a significant high frequency of FB*F allotype and low prevalence of the FS phenotype of complement factor B in schizophrenia. From the data reported, it is likely that the disorder is accompanied by alterations of the complement classical and lectin pathways, which undergo dynamic changes, depending on the illness course and the state of neuro-immune crosstalk. Recent findings, implicating complement in neurogenesis, synapse remodeling and pruning during brain development, suggest a reexamination of the potential role of complement in neurodevelopmental processes contributing to schizophrenia susceptibility. It is plausible that the multicomponent complement system has more than one dimensional association with schizophrenia susceptibility, pathopsychology and illness course, understanding of which will bring a new perspective for possible immunomodulation and immunocorrection of the disease.
Genes, Cognition and Psychosis Program IRP, NIMH, NIH, Bethesda, Maryland 20892, USA. mayilyank@mail.nih.gov
Karine R
KR
Mayilyan
Daniel R
DR
Weinberger
Robert B
RB
Sim
D001921:Brain / Q000276:immunology; D003171:Complement Pathway, Classical; D037582:Complement Pathway, Mannose-Binding Lectin; D003165:Complement System Proteins / Q000235:genetics / Q000502:physiology*; D006801:Humans; D011110:Polymorphism, Genetic; D012559:Schizophrenia / Q000276:immunology*
D003165:Complement System Proteins